211 related articles for article (PubMed ID: 23748877)
1. p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.
Okubo T; Saito T; Mitomi H; Takagi T; Torigoe T; Suehara Y; Kaneko K; Yao T
Virchows Arch; 2013 Jul; 463(1):67-77. PubMed ID: 23748877
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
[TBL] [Abstract][Full Text] [Related]
3. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of p53 protein expression in giant cell tumor of bone.
Yalcinkaya U; Ugras N; Kabul S; Ocakoglu G; Bilgen MS
Pol J Pathol; 2015 Dec; 66(4):389-96. PubMed ID: 27003771
[TBL] [Abstract][Full Text] [Related]
5. Drivers underpinning the malignant transformation of giant cell tumour of bone.
Fittall MW; Lyskjaer I; Ellery P; Lombard P; Ijaz J; Strobl AC; Oukrif D; Tarabichi M; Sill M; Koelsche C; Mechtersheimer G; Demeulemeester J; Tirabosco R; Amary F; Campbell PJ; Pfister SM; Jones DT; Pillay N; Van Loo P; Behjati S; Flanagan AM
J Pathol; 2020 Dec; 252(4):433-440. PubMed ID: 32866294
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67.
Lujic N; Sopta J; Kovacevic R; Stevanovic V; Davidovic R
Int Orthop; 2016 Nov; 40(11):2393-2399. PubMed ID: 27658412
[TBL] [Abstract][Full Text] [Related]
7. Histological and clinical characteristics of malignant giant cell tumor of bone.
Gong L; Liu W; Sun X; Sajdik C; Tian X; Niu X; Huang X
Virchows Arch; 2012 Mar; 460(3):327-34. PubMed ID: 22350004
[TBL] [Abstract][Full Text] [Related]
8. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up.
Saito T; Mitomi H; Suehara Y; Okubo T; Torigoe T; Takagi T; Kaneko K; Yao T
Pathol Res Pract; 2011 Oct; 207(10):664-9. PubMed ID: 21924561
[TBL] [Abstract][Full Text] [Related]
9. Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.
Vari S; Riva F; Onesti CE; Cosimati A; Renna D; Biagini R; Baldi J; Zoccali C; Anelli V; Annovazzi A; Covello R; Ascione A; Casini B; Ferraresi V
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142631
[TBL] [Abstract][Full Text] [Related]
10. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.
Balla P; Maros ME; Barna G; Antal I; Papp G; Sapi Z; Athanasou NA; Benassi MS; Picci P; Krenacs T
PLoS One; 2015; 10(5):e0125316. PubMed ID: 25933380
[TBL] [Abstract][Full Text] [Related]
12. Symplastic/pseudoanaplastic giant cell tumor of the bone.
Sarungbam J; Agaram N; Hwang S; Lu C; Wang L; Healey J; Hameed M
Skeletal Radiol; 2016 Jul; 45(7):929-35. PubMed ID: 27020452
[TBL] [Abstract][Full Text] [Related]
13. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
14. Triple-phase dynamic MRI: a new clue to predict malignant transformation of giant cell tumor of bone.
Chen L; Ding XY; Wang CS; Si MJ; Du LJ; Lu Y
Eur J Radiol; 2014 Feb; 83(2):354-9. PubMed ID: 24239410
[TBL] [Abstract][Full Text] [Related]
15. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
[TBL] [Abstract][Full Text] [Related]
16. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
[TBL] [Abstract][Full Text] [Related]
17. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
Han YX; Liang DY
Int J Oncol; 2012 Mar; 40(3):673-8. PubMed ID: 22076387
[TBL] [Abstract][Full Text] [Related]
18. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
19. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.
Ishihara S; Yamamoto H; Iwasaki T; Toda Y; Yamamoto T; Yoshimoto M; Ito Y; Susuki Y; Kawaguchi K; Kinoshita I; Yamada Y; Kohashi K; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Kakuda Y; Nakashima Y; Oda Y
Mod Pathol; 2022 May; 35(5):640-648. PubMed ID: 34785767
[TBL] [Abstract][Full Text] [Related]
20. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
